Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of PEGylated recombinant human G-CSF after chemotherapy in breast cancer
ChiCTR2100051414Phase 4Not yet recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in breast cancer (2 arms), sponsored by The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen). Primary endpoint: Incidence of neutropenic fever. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100051414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051414.